Additionally, the loss of NF1 can result in RAS resistance to negative feedback [19], and NF1 inactivation in melanoma harboring BRAF mutation results in a selective advantage by reversing oncogene-mediated suppression of RAS, which is driven by ERK-induced negative feedback [20]. This evidence concerns the gene NF1 and melanoma.